Zobrazeno 1 - 10
of 62
pro vyhledávání: '"Charise Gleason"'
Publikováno v:
Future Oncology. 14:3111-3121
Daratumumab gained initial US FDA approval as fourth-line therapy among relapsed and/or refractory multiple myeloma (RRMM) patients who have received at least three prior lines of therapy, including a proteasome inhibitor (PI) and immunomodulatory dr
Autor:
Charise Gleason, Roberto Mina, Jonathan L. Kaufman, Cathy Sharp, Jatin J. Shah, Leonard T. Heffner, Robert Z. Orlowski, Sagar Lonial, Jacob P. Laubach, Ajay K. Nooka, Paul G. Richardson, R. Donald Harvey, Colleen Lewis
Introduction Bortezomib plus lenalidomide and dexamethasone (VRD) is a standard induction therapy for newly diagnosed multiple myeloma (NDMM) patients. Given preclinical and clinical data suggesting the synergistic activity of the histone deacetylase
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::247ac64ff252c86ac5e974412ef88efd
https://hdl.handle.net/2318/1760019
https://hdl.handle.net/2318/1760019
Autor:
Lynne Strasfeld, Jennie R. Crews, Michelle Rajotte, Christopher R. Flowers, Randy Taplitz, Douglas K. Hawley, Loretta J. Nastoupil, Erin B. Kennedy, Eric J. Bow, Charise Gleason, Amelia A Langston, Kenneth V. I. Rolston
Publikováno v:
Journal of Clinical Oncology. 36:3043-3054
Purpose To provide an updated joint ASCO/Infectious Diseases Society of America (IDSA) guideline on antimicrobial prophylaxis for adult patients with immunosuppression associated with cancer and its treatment. Methods ASCO and IDSA convened an update
Autor:
Sagar Lonial, Marva Ollivierre Sargeant, Charise Gleason, Melanie Watson, Ajay K. Nooka, Michelle Walker, Elyse Hall Panjic
Publikováno v:
Journal of Oncology Practice. 14:414-422
Monoclonal antibodies (elotuzumab and daratumumab) are the newest class of drugs that have proven to be efficacious antimyeloma agents. Although daratumumab, a CD38 monoclonal antibody, has established its efficacy as a single agent and in combinatio
Autor:
Joel Andrews, Jonathan L. Kaufman, Charise Gleason, Sagar Lonial, Madhav V. Dhodapkar, Ajay K. Nooka
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:S129
Background Melphalan as high dose therapy (HDT) is a proven effective conditioning regimen for patients undergoing myeloma autotransplants and is associated with known peri-transplant toxicities that warrant a discussion with patients. Efforts to opt
Autor:
Charise Gleason, Danielle Roberts
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:S170
Background Advanced practice providers (APP), also known as nurse practitioners and physician assistants, are essential members of the multidisciplinary myeloma care team. APP’s within our organization train and specialize in myeloma specific clini
Autor:
Donna Catamero, Charise Gleason
Publikováno v:
Seminars in Oncology Nursing. 33:292-298
Objectives To review the use of monoclonal antibodies (mAbs) in the treatment of multiple myeloma (MM) and the management of most common side effects. Data Sources Review of journal articles related to mAbs in MM. Conclusion The therapeutic options f
Autor:
David A. Siegel, Ajai Chari, Luciano J. Costa, Charise Gleason, Ajay K. Nooka, Joseph Mikhael, Paul G. Richardson, Beth Faiman, Sundar Jagannath, Suzanne Lentzch, Kimberly Noonan
Publikováno v:
Clinical lymphoma, myelomaleukemia. 20(6)
Multiple myeloma patients have seen an unprecedented improved survival in the last decade, primarily due to the introduction of three novel classes of anti-myeloma drugs (proteasome inhibitors, immunomodulatory agents and monoclonal antibodies) and t
Autor:
Roberto Mina, R. D. Harvey, T. L. Zimmerman, Jonathan L. Kaufman, Thomas Martin, J. J. Wolf, Ajay K. Nooka, Charise Gleason, Cathy Sharp, Leonard T. Heffner, Colleen Lewis, Andrzej Jakubowiak, Sagar Lonial
Publikováno v:
Blood Cancer Journal
Blood Cancer Journal, Vol 9, Iss 1, Pp 1-9 (2019)
Blood Cancer Journal, Vol 9, Iss 1, Pp 1-9 (2019)
Proteasome (PIs) and hystone deacetylase inhibitors (HDACis) have previously shown synergistic activity in the treatment of relapesed/refractory multiple myeloma (RRMM) patients. In this phase 1 study, we combined carfilzomib, a second generation PI,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::69f9ef099caaabb2a3443866fafb75e9
http://hdl.handle.net/2318/1732448
http://hdl.handle.net/2318/1732448
Autor:
Leonard T. Heffner, Nisha Joseph, Charise Gleason, Jonathan L. Kaufman, Lawrence H. Boise, Craig C. Hofmeister, Roberto Mina, Ajay K. Nooka, Vikas Gupta, Sagar Lonial, Madhav V. Dhodapkar
Background Primary plasma cell leukemia (pPCL) is an aggressive plasma cell disorder characterized by circulating plasma cells and a poor prognosis. Although patients who have pPCL benefit from the use of stem cell transplantation (SCT) and novel age
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fad9666c592010b5e7ff7af3fe855301
http://hdl.handle.net/2318/1732772
http://hdl.handle.net/2318/1732772